Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction

Condition(s) studied

Investigational drug(s) / intervention(s)

GDMT: Predifined fast uptitration of GDMT for HFrEF with support of home monitoring.

Study summary

Research hypothesis:

Fast telemonitored medical sequencing in patients with heart failure with reduced ejection fraction (HFrEF) is safe and feasible.

Background:

Modern therapy for HFrEF offers a highly effective arsenal of drugs, devices and interventional therapies, yet mortality and morbidity remain high in the cohort. One major problem is that drug therapy introduction and up titration has been very hard to implement in a majority of HFrEF patients. Most previous telemonitoring studies have focused on the continuous monitoring of patients and the monitoring itself has been the main intervention. A potentially more effective way to use telemonitoring in heart failure patients may be to combine the technique with a medical intervention when the patients are most vulnerable to heart failure events. The best therapeutic window lies in the period after newly diagnosed heart failure or right after a recent hospitalization following worsened chronic HFrEF.

Method:

We aim to use telemonitoring for fast sequencing of heart failure drugs for patients with HFrEF.

Eligibility

Primary outcome measure(s)

• Safety and feasibility of fast telemonitored sequencing of heart failure medications in HFrEF patients — 180 days
  Incidence of treatment-emergent adverse events up to 180 days from start of sequencing.

Trial sites (1)

More Göteborg University trials in Sweden

Other trials for the same condition